Sarah Baldwin

2 weeks ago | cbsnews.com | Sara Moniuszko |Sarah Baldwin

Early season heat waves gripping the Central and Southern United States are bringing attention to the health dangers of high temperatures during pregnancy. While extreme heat can be dangerous for anybody, pregnant women are particularly at risk — and according to a report released last week, climate change is making things worse.

2 weeks ago | cbsnews.com | Sarah Baldwin

Bears testing garbage cans A 400-pound grizzly bear was trapped and killed by park staff in Yellowstone last week because it posed a risk to public safety in one of the Wyoming park's busiest areas, according to the National Park Service. The bear, an 11-year-old male grizzly, overturned bear-resistant dumpsters — some weighing 800 pounds — and pulled trash cans from their concrete bases in search of human garbage.

3 weeks ago | cbsnews.com | Sara Moniuszko |Sarah Baldwin

Men are twice as likely to die from the stress-related heart condition commonly called "broken heart syndrome" compared to women, according to new research. The condition, formally known as Takotsubo cardiomyopathy, is associated with severe emotional distress or stressful events, such as the death of a loved one. Symptoms typically include chest discomfort, shortness of breath, heart palpitations and arrhythmia, or irregular heartbeat.

3 weeks ago | cbsnews.com | Sara Moniuszko |Sarah Baldwin

The U.S. Food and Drug Administration announced on Tuesday it is starting the process of removing ingestible fluoride prescription drug products for kids from the market. The FDA said in a news release it will conduct a scientific review of the children's products by Oct. 31 with the aim of removing them from the market. It is not immediately clear whether the agency plans to ban the supplements or request that companies withdraw them.

3 weeks ago | cbsnews.com | Sara Moniuszko |Sarah Baldwin

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research. A study, published Sunday in the New England Journal of Medicine, found tirzepatide users lost about 20% of their body weight, whereas those on semaglutide lost about 14% over a 72-week period.